Fresh from the designation pipeline: orphan drugs designated in the European Union (November – December 2014)

Bibliography

• Rizzo AN, Aman J, van Nieuw Amerongen GP, et al. Targeting abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome. Arterioscler Thromb Vasc Biol 2015;35(5):1071-9
   PubMedGoogle Scholar
• Kim IK, Rhee CK, Yeo CD, et al. Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery. Crit Care 2013;17(3):R114
   PubMedGoogle Scholar
• Agency E.M. Public summary of opinion on orphan designation: Imatinib for the treatment of acute respiratory distress syndrome 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/01/WC500180391.pdf
   Google Scholar
• Giordano P, Lenato GM, Suppressa P. Hereditary hemorrhagic telangiectasia: arteriovenous malformations in children. J Pediatr 2013;163(1):179-86.e1-3
   PubMedGoogle Scholar
• Biskobing D. Update on bazedoxifene: a novel selective estrogen receptor modulator. Clin Interv Aging 2007;2(3):299-303
   PubMed Web of Science ®Google Scholar
• Karnezis TT, Davidson TM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope 2012;122(3):495-7
   PubMedGoogle Scholar
• Agency EM. Public summary of opinion on orphan designation: bazedoxifene acetate for the treatment of hereditary haemorrhagic telangiectasia. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/01/WC500180397.pdf
   Google Scholar
• Agency E.M. Public summary of opinion on orphan designation: bevacizumab for the treatment of herediatary haemorrhagic telangiectasia. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/02/WC500183213.pdf
   Google Scholar
• Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006;38(5):525-7
   PubMed Web of Science ®Google Scholar
• Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis 2011;6:80
   PubMed Web of Science ®Google Scholar
• Stolk J, Stockley RA, Stoel BC, et al. Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor. Eur Respir J 2012;40(2):306-12
   PubMed Web of Science ®Google Scholar
• Agency EM. Public summary of opinion on orphan designation: palovarotene for the treatment of fibrodysplasia ossificans progressive. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/01/WC500180398.pdf
   Google Scholar
• Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol 2006;24(5):363-73
   PubMed Web of Science ®Google Scholar
• Hozumi H, Enomoto N, Kono M. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study. PLoS ONE 2015;10(3):e0120313
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cabrera PJ, Brown S, Studer SM. S1P signaling: new therapies and opportunities. F1000Prime Rep 2014;6:109
   PubMedGoogle Scholar
• Insight A. Siponimod. 2015. Available from: http://adisinsight.springer.com/drugs/800029381
   Google Scholar
• Agency EM. Public summary of opinion on orphan designation: siponimod for the treatment of dermatomyositis. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/01/WC500180473.pdf
   Google Scholar
• Agency EM. Public summary of opinion on orphan designation: siponimod for the treatment of polymyositis. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/01/WC500180474.pdf
   Google Scholar
• Lehmann AR, McGibbon D, Stefanini M. Xeroderma pigmentosum. Orphanet J Rare Dis 2011;6:70
   PubMed Web of Science ®Google Scholar
• Yarosh D, Klein J, O’Connor A, et al. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet 2001;357(9260):926-9
   PubMedGoogle Scholar
• Zahid S, Brownell I. Repairing DNA damage in xeroderma pigmentosum: T4N5 lotion and gene therapy. J Drugs Dermatol 2008;7(4):405-8
   PubMedGoogle Scholar
• Hosseini M, Mahfouf W, Serrano-Sanchez M, et al. Premature Skin Aging Features Rescued by Inhibition of NADPH Oxidase Activity in XPC-Deficient Mice. J Invest Dermatol 2015;135(4):1108-18
   PubMedGoogle Scholar
• Agency EM. Public summary of opinion on orphan designation Pro-Pro-Thr-Val-Pro-Thr-Arg for treatment of xeroderma pigmentosum. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/01/WC500180476.pdf
   Google Scholar
• Wetzler M, Talpaz M, Kleinerman ES, et al. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med 1990;9(5):663-72
   Google Scholar
• Bachelerie F. CXCL12/CXCR4-axis dysfunctions: Markers of the rare immunodeficiency disorder WHIM syndrome. Dis Markers 2010;29(3–4):189-98
   PubMedGoogle Scholar
• Chow KY, Brotin É, Ben Khalifa Y, et al. A pivotal role for CXCL12 signaling in HPV-mediated transformation of keratinocytes: clues to understanding HPV-pathogenesis in WHIM syndrome. Cell Host Microbe 2010;8(6):523-33
   PubMedGoogle Scholar
• Agency EM. Public summary of opinion on orphan designation (E)-1-(4’-chlorophenyl)-3-(4-hydroxy-3-metoxyphenyl)prop-2-en-1-one) for the treatment of WHIM syndrome. 2014; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/02/WC500183207.pdf
   Google Scholar
• Hachet-Haas M, Balabanian K, Rohmer F, et al. Small neutralizing molecules to inhibit actions of the chemokine CXCL12. J Biol Chem 2008;283(34):23189-99
   PubMedGoogle Scholar
• McDermott DH,, Liu Q, Velez D, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood 2014;123(15):2308-16
   PubMed Web of Science ®Google Scholar
• Agency EM. Public summary of opinion on orphan designation plerixafor for the treatment of WHIM syndrome. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/02/WC500183230.pdf
   Google Scholar
• Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377(9769):942-55
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2014;15(7–8):610-17
   PubMed Web of Science ®Google Scholar
• Ito H, Wate R, Zhang J, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 2008;213(2):448-55
   PubMed Web of Science ®Google Scholar
• Agency E.M. Public summary of opinion on orphan designation: Edaravone for the treatment of amyotrophic lateral sclerosis telangiectasia. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/02/WC500183226.pdf
   Google Scholar
• Ubhi K, Low P, Masliah E. Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci 2011;34(11):581-90
   PubMedGoogle Scholar
• Stefanova N, Georgievska B, Eriksson H, et al. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox Res 2012;21(4):393-404
   PubMedGoogle Scholar
• Agency EM. Public summary of opinion on orphan designation 1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one for the treatment of multiple system atrophy. 2014; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/02/WC500183231.pdf
   Google Scholar
• Agency EM. Public summary of opinion on orphan designation: (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane7-carboxylic acid-L-lysine for the treatment of neurotrophic keratitis. 2014; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/02/WC500183227.pdf
   Google Scholar
• Sawamura D, Nakano H, Matsuzaki Y. Overview of epidermolysis bullosa. J Dermatol 2010;37(3):214-19
   PubMedGoogle Scholar